AGM/EGMJun 2, 2026, 04:07 PM
ADC Therapeutics Shareholders Approve All Proposals at 2026 AGM
AI Summary
ADC Therapeutics SA held its 2026 annual general meeting on June 1, 2026, where shareholders approved all submitted proposals. Key approvals included the 2025 financial statements, the compensation report, and the discharge of liability for the board and executive committee. Shareholders also reelected all directors, compensation committee members, the independent proxy, and PricewaterhouseCoopers SA as auditors. Additionally, binding compensation amounts for the board and executive committee were approved.
Key Highlights
- Shareholders approved 2025 financial statements with 79,705,454 votes FOR.
- All 9 directors, including Ron Squarer and Robert Azelby, were reelected for a one-year term.
- All 3 compensation committee members were reelected for a one-year term.
- PricewaterhouseCoopers SA reelected as statutory auditor for 2026 with 79,747,180 votes FOR.
- Board compensation maximum set at $2,500,000 for the 2026-2027 period.
- Executive committee fixed compensation maximum set at $2,600,000 for 2027.
- Executive committee variable compensation maximum set at $5,500,000 for 2026.
- Shareholders approved the net loss for 2025 to be carried forward.
Price Impact
More from ADCT